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Abstract 
This paper describes a micro fluorescence in situ hybridization (µFISH)-based rapid detection of cytogenetic 
biomarkers on formalin-fixed paraffin embedded (FFPE) tissue sections. We demonstrated this method in the context 
of detecting human epidermal growth factor 2 (HER2) in breast tissue sections. This method uses a non-contact 
microfluidic scanning probe (MFP), which localizes FISH probes at the micrometer length-scale to selected cells of 
the tissue section. The scanning ability of the MFP allows for a versatile implementation of FISH on tissue sections. 
We demonstrated the use of oligonucleotide FISH probes in ethylene carbonate-based buffer enabling rapid 
hybridization within < 1 min for chromosome enumeration and 10-15 min for assessment of the HER2 status in FFPE 
sections. We further demonstrated recycling of FISH probes for multiple sequential tests using a defined volume of 
probes by forming hierarchical hydrodynamic flow confinements. This microscale method is compatible with the 
standard FISH protocols and with the Instant Quality (IQ) FISH assay, reduces the FISH probe consumption ~100-
fold and the hybridization time 4-fold, resulting in an assay turnaround time of < 3 h. We believe rapid µFISH has the 
potential of being used in pathology workflows as a standalone method or in combination with other molecular 
methods for diagnostic and prognostic analysis of FFPE sections.  
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I. INTRODUCTION 
The most common cancer in females is breast cancer with 464’000 new cases alone in 2012, of which 131’000 cases 
were lethal1. While the breast cancer incidence rate has been increasing, the death rate has decreased by 40% since 
the 90ies2. This is likely due to early detection of the solid tumor linked to efforts in public health to improve awareness 
among women (at risk) and routine screening. Further, the detection of breast cancer related biomarkers through 
genomic and transcriptomic analysis allows reclassification of the tumors into molecular subtypes3,4 such as Luminal 
A (ER+, PR+, HER2-), Luminal B (low p53 mutation, ER+, PR+, HER2++), Basal-like (Triple-negative) or  HER2++ 
(Fig. 1a). Associated subtype-specific targeted therapies have led to more effective and successful treatment of patients 
and increased the survival rates3,4.  
In particular, the HER2-positive subtype is an aggressive form of breast cancer and generally associated with poor 
prognosis5. Overexpression of the HER2 membrane protein occurs in 18-20% of breast tumors6. Assessment of the 
HER2 status is therefore important to determine whether a patient qualifies for the targeted antibody-based anti-HER2 
therapy, an adjuvant to standard breast cancer chemotherapy. HER2 status assessment is not only important in breast 
cancer but there is even evidence that HER2 testing may be beneficial in gastric7 and gynecological8 malignancies. 
Techniques such as immunohistochemistry (IHC), polymerase chain reaction (PCR), enzyme-linked immunosorbent 
assay (ELISA), Southern blotting or in situ hybridization (ISH) are used to determine the HER2 status. As 
recommended by the American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP),9 IHC 
(protein level) and FISH (gene level) are the most common techniques for HER2 assessment in diagnostics.  
IHC continues to be the ‘gold standard’ for HER2 testing in most diagnostic laboratories despite the bottlenecks 
outlined below. IHC relies on antibodies binding to the HER2 antigen on the cell membrane and their subsequent 
detection by a labelled secondary antibody. The samples are graded from 0 to +3 according to the staining intensity 
of the sample (0: no expression, +1: weak expression, +2: equivocal, and +3: high expression). Only samples scored 
with grade +3 qualify the patient for the targeted anti-HER2 therapy. However, approximately 20% of results obtained 
using IHC for HER2 testing are inaccurate10. IHC results are not quantitative, since the staining intensity is assessed 
by eye resulting in subjective grading of the tumor and thus the results often differ between different laboratories. 
Further, loss of sensitivity secondary to antigenic alterations11 caused by standard fixation procedures and batch-to-
batch variations of the antibody12 can alter the staining performance. In addition, staining results are often not clear 
and reported as equivocal. In this situation, a second test – ISH as suggested by the ASCO/CAP guidelines10 – is 
needed to assess the HER2 amplification status, delaying diagnosis and requiring additional samples (Fig. 1b).  
In contrast to IHC, in situ hybridization is a cytogenetic method and, specifically for HER2 testing, relies on ISH 
probes, labelled nucleic acid sequences, that hybridize to the locus of the HER2 gene on chromosome 17 and the 
centromeric region of chromosome 1713, Fig. 1c.  It was reported that 90-95% of breast carcinomas that overexpress 
HER2 do so secondary to HER2 gene amplification14,15. An ISH result is positive if HER2/Cen17 ratio ≥2 or the 
average HER2 copy number ≥6 signals/cell, and negative if HER2/Cen17 ratio <2 according to the 2013 ASCO/CAP 
guidelines10 (Fig. 1b). ISH is a specific method16 and since each ISH signal represents a single copy of a gene, it is 
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considered more quantitative and accurate than standard IHC. Despite these merits of ISH, it is not a routine diagnostic 
procedure; it is primarily used to assess the HER2 status of the patient samples, which were reported as IHC 
equivocal10. This is the case because ISH tests are time consuming ranging from one to several days, the reagents are 
expensive, especially the FISH probes, and highly trained personnel are required in the diagnostic laboratories.  
 
FIG. 1. HER-2 classification of FFPE tumor samples. (a) Preparation steps for FFPE tissues from solid tumors. (b) 
Representative HER2 testing algorithm in diagnostics.  (c) FISH probes for HER2 classification bind to the locus of 
HER2 gene (red) and centromeric region (green) of chromosome 17. The HER2 locus is located on the q12 arm of 
chromosome 17.  
With the objective of making ISH pervasive in diagnostic laboratories, the microfluidic community has been 
developing miniaturized implementations for ISH-based analysis of cells and tissue sections. For analysis of cancer 
cell lines, devices were presented to miniaturize the assay of both adherent17–19 and non-adherent cells20–22, while other 
implementations focused on automation of the assay23,24. 
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For FISH-based microfluidic analysis of FFPE tissue sections only a few implementations have been reported; Kao et 
al. as an example focused on automation of the assay25 and reduced the FISH probe consumption from 10 μL to 2 μL 
with 16 h static hybridization resulting in a turnaround assay time of 20 h. Using flow-based FISH probe incubation 
for 4 h, Nguyen et al.26 reduced the FISH probe consumption to 2 μL and the turnaround assay time from >24 h to 8 
h. They use a PDMS device, which is contacted with the tissue section and FISH probes are loaded into the 
microchannels for hybridization. In a recent study27, they presented extra short incubation microfluidic assisted  
(ESIMA) FISH for HER2 testing of tissue sections with an incubation time of 35 min and probe consumption of 3 μL 
per test using the recently reported Instant Quality (IQ) FISH buffer28.  
While microfluidic implementations solved some bottlenecks of FISH by reducing the reagent consumption, the 
turnaround time or the work load of the FISH assay, those ‘closed’ microfluidic FISH methods are limited due to the 
need for a microfluidic chip that is clamped to the tissue section. Further, the geometry of the microchannels are fixed 
and therefore do not adapt to the varying histology between tissue sections from different sources.  
Here, we present a specific class of microfluidic-based ISH methods for rapid, economic and efficient molecular 
subtyping of tumor sections using a microfluidic scanning probe (MFP). In contrast to the traditional microfluidic 
devices, the MFP is a scanning, non-contact technology, which allows reagents to be shaped in the ‘open space’. This 
allows microfluidics-based FISH to be performed on cells in selected regions of the tissue section without physical 
contact between the device and the cytological sample. In previous work29, we introduced the concept of microfluidics-
based FISH (μFISH) with an MFP where we demonstrated spatially multiplex micro-scale FISH on cells. To 
demonstrate the diagnostic use of μFISH with an MFP, here we present methods and protocols for rapid HER2 status 
assessment of FFPE cell blocks and tissue sections while also using small volumes of FISH probes. 
II. MATERIAL AND METHODS 
A. Microfluidic probe platform 
The platform comprised a standard inverted microscope, sub-micrometer precision stages, syringe pumps connected 
to a microfabricated silicon-glass hybrid MFP head, mounted to a custom-made z-stage (Fig. S1, supplementary 
material). The head used for all experiments was a microfabricated device that localizes liquids on the cytological 
samples. The head itself contained four microchannels, which open up at the apex of the head and form apertures: two 
for injection and two for aspiration of liquids to and from the surroundings. The channel dimensions of the inner two 
apertures were 100 × 100 μm2 and the dimensions of the outer two apertures 100 × 200 μm2. The microfabrication of 
the head was described elsewhere30. The head was connected to glass syringes (Hamilton, 1705 TLLX) via adapters 
and tubings (IDEX, Tygon) and an 8-port circular Dolomite connector. Via control of the linear stages (Lang GmbH, 
Hüttenberg, Germany), x- and y-position of the head relative to the substrate was controlled with sub-micrometer 
accuracy. The MFP head was mounted to a z-stage on the microscope via a mounting plate (Fig. S1, supplementary 
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material). An environmental chamber (Life Imaging Services GmbH, ‘The Cube and the Box’) for temperature control 
was placed around the platform.  
B. Preparation of FFPE samples for FISH 
FFPE MCF-7 and BT-474 cell blocks (CellMax™ FFPE Control Cell Line Slides - MCF-7 and BT-474) were 
purchased from AMS Biotechnology and 5 μm thick breast tumor tissue microarrays (Her2B) were purchased from 
US Biomax Inc. A datasheet with HER2 IHC data was provided from the vendor. The baking and heating steps were 
performed on a hotplate (Cimarec+™, Cat. No. BARNHP88857105). First, the FFPE sample was baked at 60 °C for 
1 h. Next, the sample was dewaxed in xylene (Merck, Cat. No. 1082972500) for 10 min. Then the sample was 
transferred to an ethanol-containing (Sigma Aldrich, Cat. No. 02860) glass beaker for 3 min and then dried completely 
at RT. For antigen retrieval, the sample was transferred in a solution of 0.08× saline sodium citrate (SSC) in ddH2O 
heated to 98 °C for 20 min (from 20× SSC stock, 3 M NaCl, 0.3 M sodium citrate, pH 7.0, Thermo Fisher Scientific, 
Cat. No. 15557-044). Then the sample was rinsed with ddH2O for 5 min and dried at RT. Next a hydrophobic barrier 
was drawn around the section with a pap pen (Sigma, Cat. No. Z377821) and dried at RT. The section was then 
digested using pepsin at 37 °C for 10-20 min (Milan Analytica AG, Cat. No. PSS060) and subsequently rinsed with 
ddH2O for 5 min. Subsequently, the sample was dried and the pre-treated samples were covered with FISH buffer 
(Sections III.A & C, KBI-FHB, Leica Biosystems) or an aqueous ethylene carbonate solution (Section III.B.), covered 
with a cover slip and denatured at 65-72 °C for 10 min. After this step, the cover slip was removed, the slide rinsed 
with prewarmed 1×SSC and hybridization experiments were performed.  
For benchtop FISH control experiments, the FISH probes were diluted as specified by the manufacturer’s protocol in 
FISH buffer (KBI-FHB). This hybridization mix was subsequently pipetted onto the pre-treated FFPE cell blocks, 
which were covered with a cover slip and denatured at 72°C for 10 min. After denaturation the slide was incubated 
fpr hybridization at 37°C overnight. After hybridization, the slides were washed 2 times to wash non-specifically 
bound probes with 0.1 % IGEPAL CA-630 in 2× SSC (v/v) for 1 min at RT and with 0.3 % IGEPAL CA-630 in 0.4
× SSC (v/v) at 72°C for 2 min (Sigma Aldrich, Cat. No. I8896). Subsequently, an additional wash was performed 
with 1× SSC at RT for 1 min. The cells were then mounted with mounting medium containing DAPI (Thermo Fisher 
Scientific, Cat. No. S36938) for inspection.  
 
C. FISH probe preparation and FISH probe loading into the MFP 
The Cen17 probes were prepared from a mix of seven centromere 17-specific oligonucleotides with 3’ and 5’ Cy3 
labels (SI Table S2), which were purchased from Integrated DNA Technologies (Coralville, Iowa). The sequences 
were adapted from Ref.31 The 10× FITC-labelled HER-2 SureFISH probe was purchased from DAKO (Cat. No. 
G100046G-8). For recirculation experiments SSC buffer was used as the hybridization buffer. For HER2 
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classification, an ethylene carbonate (EC) buffer based on Ref.28 was prepared: 15% v/v ethylene carbonate (Sigma, 
Cat. No. E26258), 20% v/v dextran sulfate (Sigma, Cat. No. D8906), 0.67×SSC and 600 mM NaCl (Sigma, Cat. No. 
71378) in nuclease-free water (Sigma, Cat. No. W4502).  
For all experiments the Cen17 probes were used at a total concentration of 28 nM. The HER2 probe was diluted 1:10 
in Cen17 containing EC-buffer. These FISH probes were denatured at 75 °C (formamide) or 66-68 °C (ethylene 
carbonate) for 5–10 min in a PCR cycler (QIAGEN, Rotor-Gene Q). To visualize the footprint indirectly, Hoechst dye 
was added to the probes at a concentration of 0.2 μg mL–1 (Thermo Fisher Scientific, Cat. No. H3570). Subsequently 
these denatured probes were pipetted into a PCR cap and from there aspirated into the inner injection aperture of the 
MFP head. 
D. μFISH protocol 
One hour prior to performing the experiment, the environmental chamber around the MFP platform was heated to 
45°C. After FISH probe loading into the MFP head, the pre-treated sample was transferred to the sample holder of the 
MFP platform, and the apex of the head was positioned 20-30 μm above the section. Subsequently, a hierarchical 
hydrodynamic flow confinement (hHFC) of FISH probes was contacted with the substrate as depicted in Fig. 2. In 
this flow configuration, two processing liquids were contacted with selected cells simultaneously: FISH probes were 
confined between the inner apertures and injected with flow rate Qi2 and the wash buffer (1× SSC) was confined 
between the outer pair of apertures and injected with Qi. For HER2 assessment experiments, the flow rates were set to 
10, 7 nL min–1 (Qi1, Qi2) and –7, –100 nL min–1 (Qa1, Qa2), accordingly. For the chromosomal enumeration and 
recirculation experiments, the flow rates were set to 100, 200 nL min–1 (Qi1, Qi2) and –0.2, –2 μL min–1 (Qa1, Qa2), 
respectively. After 5-15 min of interaction of the hHFC with the cells (equivalent to 5-15 min of incubation), Qi2 was 
stopped, and the nuclei were washed with 1× SSC flowing between the outer apertures for 2 min. To avoid reflections, 
the head was positioned away from the slide before imaging. The footprint for all MFP-based FISH experiments was 
0.096 mm2. 
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FIG. 2. Schematics of the µFISH assay implemented with an MFP on a tissue section. (a) At the apex of the scanning 
head, FISH probes are confined hydrodynamically. FISH signals are present in cells in the region of the flow 
confinement (footprint). (b) Hydrodynamic flow confinements: In flow configuration 1, FISH probes (green) are 
confined between the inner pair of apertures. During incubation, the probe confinement is in contact with the 
cytological sample. After incubation, the inner flow is stopped and the cells from the sample are rinsed with the wash 
buffer (blue) from the outer injection aperture (flow configuration 2). Subsequently, FISH signals are inspected. 
E. Image acquisition and processing 
Both, the endpoint observation for conventional FISH and the real-time observation for μFISH were performed using 
an inverted microscope at 10×, 40× and 60× magnification (Nikon Eclipse Ti-E with objectives CFI Plan Fluor DLL 
10×, ELWD 40× and ELWD 60×, respectively). An LED lamp (Sola, Lumencor) and filter cubes FITC (F36-525), 
Cy3 (F36-542) and DAPI (F36-498) from AHF Analysentechnik were used for excitation and emission control. Image 
acquisition was performed using a Hamamatsu ORCA-flash 4.0 camera controlled with the NIS Elements Basic 
Research software (Nikon Instruments Europe, V.4.0). Image processing of raw images as well as merging were done 
using the open-source FIJI (ImageJ) software (http://fiji.sc/Fiji) (Fig. S3, supplementary material). 
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III. RESULTS 
A. Oligo-based probes for chromosomal enumeration in FFPE tissue sections with <5 min incubation 
We aimed to enumerate the copy numbers of chromosome 17 in FFPE tissue sections, and for this we adapted the 
MFP-based FISH method29. In contrast to the ‘fresh’ cells we used for our previous study, FFPE samples undergo a 
series of preparation steps affecting the sample integrity32–38. Formaldehyde fixation of cytological samples is 
associated with DNA modifications32, DNA fragmentation33 and DNA-protein crosslinking34, which affects the DNA 
integrity. Further, the crosslinked matrix can reduce the FISH probe mobility, i.e. the FISH probe penetration through 
the sample and the target accessibility, thereby lowering the efficiency in hybridization of probes to the target. To 
enable rapid FISH-based chromosomal enumeration on FFPE tissue sections, we: (i) adapted the FISH probe and 
moved to using short oligonucleotides, and (ii) optimized the composition of the hybridization buffer. DNA mobility 
in the cell and cell nucleus decreases as the length of the DNA increases39. Similarly, the mobility of FISH probes in 
the cell decreases with increasing length and thus it has been found that an optimal length for oligonucleotide FISH 
probes is 18-50 nucleotides (nt)40. Longer  probes  will  result  in  increased hybridization times and low synthesis 
yields; on the other hand, shorter probes will result in reduced specificity40. To yield rapid FISH we therefore used 18 
nt long oligonucleotide probes as the Cen17 probe (Table SI, S2 in supplementary material) to visualize the 
centromeric region of chromosome 17. Further, we prepared a formamide-free hybridization buffer and used the 
traditional FISH buffer (~50% formamide) only for denaturation of the chromosomal DNA of the sample. 
Interestingly, FISH signals appeared as early as ~30 s after initiating the flow of FISH probes over cells in the selected 
area of the tissue sections, in our experiments. Strong signals of the Cen17 probes in the nuclei of FFPE breast tumor 
tissue sections were detected within < 5 min (Fig. 3). Thus, the short DNA FISH probes are characterized with a high 
mobility through the crosslinked matrix. In addition, the hybridization process itself is likely accelerated by the change 
of hybridization buffer to the formamide-free composition. Formamide is a denaturation agent, which interferes with 
the hydrogen bonds forming during hybridization41, thereby slowing down the hybridization. 
 
9 
 
 
FIG. 3. µFISH-based chromosomal enumeration in FFPE tumor sections (i) In situ hybridization occurs only in 
the cell nuclei (blue) within the area of the flow confinement (green). The tear shape is caused by the asymmetry 
between the injection and aspiration rate (i,ii). Fluorescent micrographs of Cen17 FISH signals (green) before (ii) 
and after image processing (iii,iv). 
B. µFISH-based HER2 testing for diagnosis of breast cancer tissue sections.  
We then posed the question, whether this MFP-based method can be used in a diagnostic context, for HER2 testing 
on FFPE cell blocks and tissue sections. To achieve this, we used a mix of oligo-based HER2 and Cen17 probes. 
However, HER2-specific probes did not create FISH signals within 5 min incubation with MFP-based FISH on FFPE 
samples, when diluted in in 1 SSC. The chosen HER2 probes are commercially available synthetic oligonucleotide 
probes and specifically designed to the HER2 locus42. Cen17 FISH probes bind repetitive elements of chromosome 
17 and each probe sequence has ~100 targets per chromosome. In contrast, the HER2 locus contains fewer repetitive 
elements and each HER2-specific probe sequence binds a unique target within the HER2 locus. Thus, the probability 
of a Cen17 finding its target is higher than the probability of a HER2 probe finding its target. Further, HER2 probes 
used here are long oligonucleotide probes42,43 with a length of ~ 150 nt. Since DNA mobility is reduced with increasing 
length39, the HER2 probes require more time for hybridization than the 18 nt Cen17 probe. 
To accelerate the hybridization reaction, we therefore modified the buffer by adding dextran sulfate as a volume 
exclusion agent44 and ethylene carbonate (EC), adapted from the Instant Quality (IQ) FISH method28. Performing 
FISH probe incubation of the probe mix in EC-buffer using the MFP, we were able to assess the HER2 status of both 
FFPE cell blocks and breast cancer tissue sections within 10 min (cells) and 15 min (tissue) incubation time (Fig. 
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4.a,b). Even at flow rates of 7 nL min-1 we were able to establish a stable flow confinement. Further, since the probe 
mix is viscous, the flow confinement was still in contact with the cells at these low flow rates and a surface-to-apex 
distance d = 20 µm. After less than one minute, the Cen17 signals were saturated and HER2 signals appeared within 
15 min incubation (Fig. 4.a,b). 
We specifically chose MCF-7 (HER2 negative) and BT-474 (HER2 positive) cell blocks for validation of the MFP-
based FISH method and quantified the HER2/Cen17 ratios in 20 cells as recommended by the ASCO/CAP guidelines 
after both benchtop FISH using a pipette and µFISH experiments (Fig. S4, supplementary material for fluorescent 
micrographs after benchtop experiments). The HER2/Cen17 ratios calculated for both on-bench and MFP-based FISH 
were experiments were comparable for as illustrated in the graph in Fig. 4.c. The ratio was 0.82 (MFP) and 0.64 
(benchtop) in MCF-7 cells and in BT-474 cells, the ratio was 2.8 (MFP) and 3.0 (benchtop). 
In addition, we tested the µFISH method on FFPE tissue sections and assessed the HER2/Cen17 ratio in 20 cells from 
two tissue cores from a tissue microarray. As depicted in Fig. 4.d the HER2 status assessed with µFISH matched the 
IHC data of the datasheet from the tissue microarray.  
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FIG. 4.  µFISH-based HER2 assessment in FFPE cell blocks and tumor sections. (a) Fluorescent micrographs for 
qualitative validation of µFISH for HER2 assessment on HER2 amplifying (BT-474) and HER2 non-amplifying (MCF-
7) FFPE cell blocks. (b) Validation of µFISH-based HER2 assessment on nuclei (outlined) of HER2-amplified (left) 
and HER2 non-amplified (right) FFPE invasive ductal carcinoma tissue cores from a tissue microarray. (c) 
HER2/Cen17 ratios in MCF-7 and BT-474 cells in FFPE cell blocks assessed with benchtop and MFP-based FISH. 
Error bars present the standard error of the mean for n=20 measurements. (d) Quantified HER2/Cen17 ratio from 20 
cells of the tissue cores illustrated in (b) comparing to the HER2 status from the tissue microarray datasheet.  
C. FISH probe recirculation for efficient use of FISH probes 
For a more economic use of FISH probes, we tested the concept of recirculation on FFPE cell blocks. In a classical 
flow confinement, a processing liquid is confined between two apertures at the apex of the MFP head and the surface, 
in the presence of an immersion liquid. Since the aspiration rate is set to be approximately 3-fold higher than the 
injection rate to ensure a stable flow confinement, immersion liquid will be aspirated together with the processing 
liquid into the aspiration channel, resulting in an ~3-fold dilution of the processing liquid. The addition of two extra 
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apertures, allows the processing liquid to be nested within a confinement of a second liquid, resulting in a hierarchical 
flow confinement46. Specifically, for MFP-based FISH, in a hierarchical hydrodynamic flow confinement the FISH 
probes are confined between the inner two apertures, while between the outer two apertures, a wash buffer is confined 
to nest the FISH probes (Fig. 5a). Since the outer aspiration rate is high with Qa2>>Qa1 and maintains a stable flow 
confinement, the inner injection and aperture rates can be set to Qi2=|Qa1|. Due to this symmetry between Qi2 and Qa1, 
a liquid injected with Qi2 is aspirated by Qa1 with minimal dilution. Therefore, a liquid confined between the inner two 
apertures can be re-injected and thus recirculated after inversion of the flow rates: Qi2↔Qa1, Qi1↔Qa2 (Fig. 5). 
The graph in Fig. 5b illustrates the probe dilution per recirculation cycle for 1 µL of Cen17 probes in 1 SSC with a 
probe injection rate Qi2 of 0.2 µL min-1, 5 min switching intervals and a surface-to-apex distance d = 20 µm. We 
measured the fluorescence intensity for each recirculation cycle and normalized the intensity with respect to the initial 
fluorescence intensity of the confined probes. As illustrated in Fig. 5b, the FISH probes are diluted by ~ 6% per 
recirculation cycle. This dilution is likely due to the slight asymmetry of the flow profile resulting in a small flow 
from the immersion liquid into the inner aspiration aperture and the loss of FISH probes aspirated into the outer 
aspiration aperture. 
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FIG. 5. Recirculation of FISH probes using the MFP for FISH probe budgeting on MCF-7 cell blocks. (a) 
Switching between the two states for FISH probe (green) recirculation. (b) Dilution of FISH probes as a function of 
recirculation cycle for n=3 experiments (black dots) and averaged FISH signal intensity of n=12 FISH signals for 10 
testing areas (blue dots). Error bars present the standard error of the mean. (c) Schematics of 10 FISH tests performed 
by recirculating 1 μL Cen17 probes on an MCF7 cell block. (i) Micrograph of nuclei within the last test region, test 
region 10, after 5 min incubation. (ii,iii) FISH signals in the processed nuclei in test region 10. (d) Micrograph of the 
MFP in operation. 
We next investigated the possibility of using a small volume of FISH probes for multiple FISH tests. In a proof-of-
concept experiment we performed a sequence of ten FISH tests on an MCF-7 cell block by recirculating a defined 
volume of Cen17 probes ten times between the inner pair of apertures for 50 min with 5 min incubation time per FISH 
footprint (0.096 mm2) (Fig. 5.c,d). At discrete time intervals of 5 min, we inverted the flow rates of FISH probes 
through the MFP microchannels and positioned the probe head to the next testing area. Cen17-specific signals were 
present in all cells within the 10 testing areas. Interestingly, even with 40% of the initial FISH probe concentration 
after 10 recirculation cycles, hybridization was efficient to yield FISH signals as strong as 80% of the initial signal 
intensity within 5 min incubation (Fig. 5.b,c). 
IV. DISCUSSION 
Operating at flow rates of 7 nL min-1 and 15 min incubation time results in a probe consumption of 105 nL per FISH 
test, which is a ~100-fold reduction compared with the standard FISH protocol. The assay turnaround time for MFP-
based HER2 testing is <3 h, which is comparable with the turnaround time of an IHC assay. This potentially makes it 
feasible to perform both FISH and IHC-based tests simultaneously, rather than performing FISH tests only on 
equivocal patient’s samples. Such a multimodal approach presents a more robust HER2 testing workflow than 
currently implemented in diagnostic laboratories and could have implications for not only breast cancer but also 
gastric7 or gynecological8 subtyping. This would further allow the healthcare professionals to make treatment 
decisions sooner, thereby saving precious time for the patient. 
The processed area for MFP-based FISH measures 0.096 mm2 and captures 300 cells from an FFPE tissue section 
depending on the amount of connective tissue, tissue type and cell density of the sample. For a FISH-based diagnosis, 
the 2013 ASCO/CAP guidelines suggest to at least count the FISH signals in 20 non-overlapping nuclei from the 
tumor cells10. Tumor cells in solid tumors are often clustered within the abnormal areas of the tissue and therefore in 
one MFP footprint, we capture enough cells for a diagnosis. A challenge of analyzing tissue sections is to perform the 
µFISH assay in the cancerous regions of the heterogeneous patient sample. However, abnormal regions of the tissue 
can be identified using the cell autofluorescence before MFP-based FISH. 
In the MFP-based FISH implementation, convection-based delivery of reactants accelerates the reaction by enhancing 
the mass transport; the reagent consumption is, however, dependent on the reaction duration, because the incubation 
step is flow-based. To overcome this, we made use of the capability of the MFP to recirculate liquids and demonstrated 
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that a finite volume of FISH probes can be recycled, and the probes are used more efficiently. Recirculation of probes 
has several advantages. It allows multiple areas of a heterogeneous sample or multiple samples to be probed using one 
volume of probes. Further, even slow-hybridizing FISH probes such as long FISH probes of > 500 nt can now be 
hybridized with the MFP without increasing the probe consumption.  
V. CONCLUDING REMARKS 
We introduced methods and protocols for rapid detection of an important breast cancer biomarker, human epidermal 
growth factor receptor 2 (HER2), in tissue sections. We make use of a microfluidic probe technology and perform 
localized FISH probe incubation with cells in selected regions of tissue sections and cell blocks. This is done by 
confining FISH probes hydrodynamically on the tissue section at the micrometer length-scale without needing to 
construct physical walls. By using minimal probe amounts and also minimal amounts of the scarce cytological sample, 
the MFP-based FISH implementation presents a valuable method for diagnosis of breast cancer biopsies. 
The focus of this work was to overcome the rate-limiting step in FISH, the probe hybridization, by using an MFP. 
However, combining recently reported features for liquid heating47 and liquid switching48 in the MFP head, it is 
possible to implement the entire FISH protocol and automate the assay with the MFP. A shortcoming of the used 
device is currently the low throughput. There is the possibility to form multiple confinements and process a larger 
number of samples simultaneously by adapting the design of the MFP device. The shape and the footprint dimensions 
can be adapted by changing the aperture geometries which could range from 1 × 1 µm2  up to 1.2 × 0.3 mm2 for the 
vertical MFP49,50. To further reduce the time of tests, one approach is to increase the concentration of the FISH probes. 
Phung et al. recently focused a high concentration plug of FISH probes with isotachophoresis in a microfluidic channel 
for FISH analysis of bacteria51. Combining this approach with the HFC to move a ‘static’ high concentration plug for 
more rapid FISH analysis might be possible by applying a counterflow. 
Going forward we expect to adapt the method for multiplexed RNA FISH for research applications using branched 
RNA probes. The recently developed RNA ISH methods revealed new biomarkers, which may become diagnostic or 
prognostic markers in the future52–54. Overall, µFISH supports our vision of tissue microprocessing to implement 
several bio-analytical tests on limited biopsy samples.  
SUPPLEMENTARY MATERIAL 
See supplementary material for further information on the MFP platform, image processing with ImageJ, bench-top 
FISH controls and Cen17 probe sequences. 
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